Isavuconazole (ISAV) As Primary Anti-Fungal Prophylaxis in Acute Myeloid Leukemia or Myelodysplastic Syndrome: An Open-Label, Prospective Study

Conclusions: These results demonstrate ISAV to be a safe and effective alternative for antifungal ppx in treatment-naïve pts with AML/MDS undergoing induction therapy with a variety of different regimens. ISAV's weak inhibition of P-glycoprotein and lack of risk of QT prolongation may make ISAV particularly attractive for antifungal ppx in the era of recently approved or emerging AML therapies such as enasidenib, ivosidenib, midostaurin and quizartinib.DisclosuresBose: CTI BioPharma: Research Funding; Constellation Pharmaceuticals: Research Funding; Blueprint Medicines Corporation: Research Funding; Celgene Corporation: Honoraria, Research Funding; Incyte Corporation: Honoraria, Research Funding; Astellas Pharmaceuticals: Research Funding; Pfizer, Inc.: Research Funding. Wiederhold: Astellas Pharmaceuticals: Research Funding. Kadia: Celgene: Research Funding; Amgen: Consultancy, Research Funding; Jazz: Consultancy, Research Funding; Pfizer: Consultancy, Research Funding; Novartis: Consultancy; Abbvie: Consultancy; Abbvie: Consultancy; BMS: Research Funding; Pfizer: Consultancy, Research Funding; BMS: Research Funding; Novartis: Consultancy; Amgen: Consultancy, Research Funding; Takeda: Consultancy; Celgene: Research Funding; Takeda: Consultancy; Jazz: Consultancy, Research Funding. Ravandi: Abbvie: Research Funding; Xencor: Research Funding; Xencor: Research Funding; Jazz: Honoraria; Orsenix: Honoraria; Jazz: Honoraria; Bristol-Myers Squibb: Research Funding; Seattle Gen...
Source: Blood - Category: Hematology Authors: Tags: 613. Acute Myeloid Leukemia: Clinical Studies: Poster II Source Type: research

Related Links:

Publication date: 17 September 2019Source: Cell Reports, Volume 28, Issue 12Author(s): Anetta Ptasinska, Anna Pickin, Salam A. Assi, Paulynn Suyin Chin, Luke Ames, Roberto Avellino, Stephan Gröschel, Ruud Delwel, Peter N. Cockerill, Cameron S. Osborne, Constanze BoniferSummaryAcute myeloid leukemia (AML) is associated with mutations in transcriptional and epigenetic regulator genes impairing myeloid differentiation. The t(8;21)(q22;q22) translocation generates the RUNX1-ETO fusion protein, which interferes with the hematopoietic master regulator RUNX1. We previously showed that the maintenance of t(8;21) AML is depend...
Source: Cell Reports - Category: Cytology Source Type: research
Authors: Petrakis I, Kontogiorgis C, Nena E, Athanasakis K, Gougoula V, Kotsianidis I, Constantinidis TC Abstract Introduction: Real-world effectiveness of hemato-oncology pharmaceuticals may not necessarily mimic clinical trial efficacy results, mainly due to demographic and clinical practice variability. The aim of this review was to systematically assess the availability of real-world evidence (RWE) and the transferability of clinical trial (CT) efficacy results to real life, for novel agents recently approved to manage lymphomas, leukemias and multiple myeloma. This is the largest cross-indication review compar...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Publication date: Available online 17 September 2019Source: Biocatalysis and Agricultural BiotechnologyAuthor(s): Sthéfane Guimarães Araújo, William Gustavo Lima, Maria Eduarda Amaral Pinto, Marcela Ísis Morais, Nívea Pereira de Sá, Susana Johann, Carlos Augusto Rosa, Luciana Alves Rodrigues dos Santos LimaAbstractThe medical importance of invasive fungal diseases (IFD) contrasts with the limited therapeutic arsenal available and the increasing resistance rate of pathogenic fungi. Thus, the search for news antifungal drugs is imperative. Many studies highlight the antimicrobial act...
Source: Biocatalysis and Agricultural Biotechnology - Category: Biotechnology Source Type: research
This study revealed that xylanase production was favored by a substrate liquefied using the optimum pH (4.8) and temperature conditions (50 °C) of the commercial enzymatic preparation (2.8 FPU/g solids), while the liquefaction time was not significant above 6 h. The proposed strategy resulted in xylanase activity 5-fold higher than for a cultivation with non-liquefied substrate (control). These findings should contribute to the development of xylanase production processes using high solids loading submerged cultivation in conventional large-scale bioreactors.
Source: Biocatalysis and Agricultural Biotechnology - Category: Biotechnology Source Type: research
Publication date: 15 January 2020Source: Journal of Molecular Structure, Volume 1200Author(s): Meng-Xue Zhou, Ning Ren, Jian-Jun Zhang, Da-Qi WangAbstractFour novel lanthanide coordination complexes, [La(p-ClBA)3(5,5′-DM-2,2′-bipy)H2O]n (1), [Ln(p-ClBA)3(5,5′-DM-2,2′-bipy)H2O]2 (Ln = Sm 2, Eu 3, Gd 4) were obtained from the reaction between p-chlorobenzoic acid (p-ClHBA), 5,5′-dimethyl-2,2′-bipyridine (5,5′-DM-2,2′-bipy) and lanthanide nitrate under solvothermal conditions. Single crystal X-ray diffraction analysis showed that complex 1 is a 1D chain structure, crystalliz...
Source: Journal of Molecular Structure - Category: Molecular Biology Source Type: research
CONCLUSION: Certain decontamination protocols and regulations must be defined to eliminate bacteria and fungi, as both were present in samples from all of the laboratories. PMID: 31522164 [PubMed - in process]
Source: Journal of the International Academy of Periodontology - Category: Dentistry Tags: J Int Acad Periodontol Source Type: research
Condition:   Acute Myeloid Leukemia Interventions:   Drug: Gemtuzumab Ozogamicin 147;   Drug: Gemtuzumab Ozogamicin 1;   Drug: Glasdegib;   Drug: Placebo Oral Tablet Sponsor:   University Hospital Heidelberg Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndromes Intervention:   Drug: ASTX727 Sponsor:   Astex Pharmaceuticals, Inc. Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Intervention:   Drug: Ibrutinib Sponsors:   The First Affiliated Hospital with Nanjing Medical University;   Xian-Janssen Pharmaceutical Ltd. Recruiting
Source: - Category: Research Source Type: clinical trials
Conditions:   B-cell Acute Lymphoblastic Leukemia;   Diffuse Large B-cell Lymphoma Intervention:   Biological: Tisagenlecleucel Sponsor:   Novartis Pharmaceuticals Not yet recruiting
Source: - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Myeloid Leukemia | Aspergillosis | Aspergillus | AstraZeneca | Biotechnology | Cancidas | Candida | Caspofungin | Fungal Infections | Genetics | Insurance | Leukemia | Myelodysplastic Syndrome | Pfizer | Pharmaceuticals | Respiratory Medicine | Study | Toxicology